Towards personalised medicine in lung and thymus neuroendocrine tumours
Mené sur 124 patients adultes atteints d'une tumeur carcinoïde du poumon ou du thymus de stade avancé, cet essai international de phase II évalue l'efficacité, du point de vue de l'absence de progression de la tumeur, et la toxicité du pasiréotide à action prolongée et de l'évérolimus, seuls ou en combinaison
A personalised treatment approach is increasingly the aim of oncology care. In the gastrointestinal tract, an effective grading system has been devised for neuroendocrine tumours to guide treatment strategies and help malignancy stratification, but for lung and thymus carcinoids this information has remained less reliable, especially in metastatic tumours where diagnostic material is limited and for cases with similar histology.